- Phathom Pharmaceuticals (NASDAQ: PHAT) currently exhibits negative capital efficiency, with its Return on Invested Capital (ROIC) significantly lower than its Weighted Average Cost of Capital (WACC).
- This trend of value destruction is common among biopharmaceutical companies in the clinical stage due to substantial research and development (R&D) spending.
- Among its peers, Arcutis Biotherapeutics (NASDAQ: ARQT) stands out with a positive ROIC, indicating a more efficient capital allocation strategy despite still being below its WACC.
Phathom Pharmaceuticals (NASDAQ: PHAT) is a leading biopharmaceutical company focused on developing and commercializing innovative treatments for gastrointestinal diseases. To assess its investment performance and how effectively it utilizes its capital, we examine its capital efficiency. This critical financial metric involves comparing its Return on Invested Capital (ROIC) to its Weighted Average Cost of Capital (WACC).
ROIC quantifies the profit a company generates from its invested capital, reflecting its operational efficiency. Conversely, WACC represents the average rate of return a company expects to pay to its investors, encompassing both debt and equity financing. A fundamental principle of financial analysis is that if ROIC exceeds WACC, the company is successfully creating shareholder value. Currently, Phathom Pharmaceuticals reports an ROIC of -53.45% and a WACC of 15.49%.
Given that Phathom Pharmaceuticals’ ROIC is substantially lower than its WACC, the company is currently destroying value with each dollar invested. This scenario is frequently observed among biopharmaceutical companies in the clinical stage, where significant research and development (R&D) spending is required before product commercialization and revenue generation.
A broader look at the biotech sector analysis reveals this trend is widespread among competitors. For example, Crinetics Pharmaceuticals (NASDAQ: CRNX) reports an ROIC of -40.83%, and NGM Biopharmaceuticals (NASDAQ: NGM) shows an ROIC of -98.49%. In contrast, Arcutis Biotherapeutics (NASDAQ: ARQT) distinguishes itself as the most effective capital allocator within this peer group, achieving an ROIC of 1.05%.
Although Arcutis Biotherapeutics’ ROIC of 1.05% remains below its WACC of 12.08%, it is noteworthy as the sole company in this peer group to achieve a positive return. In a challenging biotech industry where companies frequently experience significant cash burn for extended periods, attaining a positive ROIC represents a crucial milestone, highlighting Arcutis Biotherapeutics’ stronger financial health and potential competitive advantage.
